ProCE Banner Activity

Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Podcast Episodes
In this podcast episode, listen to Chris Parker, MD, and Bertrand Tombal, MD, PhD, as they discuss clinical implications of the latest data from ASCO 2021 on using radium-223, PSMA lutetium, and bone health approaches for the treatment and management of patients with metastatic castration-resistant prostate cancer.

Released: July 20, 2021

Expiration: July 19, 2022

Share

Faculty

Chris Parker

Chris Parker, MD

Professor of Prostate Oncology
Institute of Cancer Research
Clinical Oncologist
Department of Uro-oncology
Royal Marsden Hospital
Sutton, Surrey, United Kingdom

Bertrand Tombal

Bertrand Tombal, MD, PhD

Professor of Urology
Institut de Recherche Clinique (IREC)
Chairman, Department of Surgery
Cliniques universitaires Saint-Luc
Brussels, Belgium

Supporters

Supported by an educational grant from

Bayer HealthCare

Faculty Disclosure

Primary Author

Chris Parker, MD

Professor of Prostate Oncology
Institute of Cancer Research
Clinical Oncologist
Department of Uro-oncology
Royal Marsden Hospital
Sutton, Surrey, United Kingdom

Chris Parker, MD, has disclosed that he has received consulting fees from Bayer and Myovant and fees for non-CME/CE services from Janssen.

Bertrand Tombal, MD, PhD

Professor of Urology
Institut de Recherche Clinique (IREC)
Chairman, Department of Surgery
Cliniques universitaires Saint-Luc
Brussels, Belgium

Bertrand Tombal, MD, PhD, has disclosed that he has received funds for research support from Astellas and Bayer; consulting fees from Amgen, Astellas, Bayer, Ferring, Janssen, Novartis/Advanced Accelerator Applications, Sanofi, and Myovant; and fees for non-CME/CE services from Amgen, Astellas, Bayer, Ferring, Janssen, Novartis/Advanced Accelerator Applications, Sanofi, and Myovant.